The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Epimu00e8de SA, startups are often financed by Vesalius Biocapital Partners, Sambrinvest, SFPI-FPIM. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Vesalius Biocapital Partners.
The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Diagenode, Endo Tools Therapeutics, Ncardia. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 5 - 10 millions dollars. The high activity for fund was in 2016.
Related Funds
| Fund Name | Location |
| Asset Alliance Corp. | New York, New York, United States |
| BankDhofar | Muscat, Muscat, Oman |
| BGS Venture | Canada, Ontario, Toronto |
| Cambridge University Press | - |
| Chongda Touzi | China, Shanghai |
| D64 Ventures | - |
| Digital Century Capital | New York, New York, United States |
| Geneva Cantonal Bank | Geneva, Geneve, Switzerland |
| HuoMao TV | China, Shanghai |
| Mano Group Ltd | England, London, United Kingdom |
| PICC Health Insurance | Beijing, Beijing Shi, China |
| Plymouth Growth Partners | Ann Arbor, Michigan, United States |
| Provident Capital | Gurgaon, Haryana, India |
| Qianxi Taihe Chuangtou | China, Jiangsu, Nanjing |
| Spok Holdings | Springfield, United States, Virginia |
| Telemedia | Bellefonte, Pennsylvania, United States |
| U.S. Environmental Protection Agency | District of Columbia, United States, Washington |
| Uji Capital | - |
| Yarui Baichang Touzi | - |
| Yuanzhi Chuang Tou | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Imcyse | $25M | 17 Feb 2021 | Liège, Liège, Belgium | ||
Endo Tools Therapeutics | $5M | 11 Feb 2019 | Belgium, Hainaut | ||
Ncardia | $12M | 17 Nov 2017 | Leiden, South Holland, Netherlands |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Imcyse | $25M | 17 Feb 2021 | Liège, Liège, Belgium | ||
Endo Tools Therapeutics | $5M | 11 Feb 2019 | Belgium, Hainaut | ||
Ncardia | $12M | 17 Nov 2017 | Leiden, South Holland, Netherlands |
